Skip to main content

Table 4 Risk factors for proven/probable IFD among allo-HSCT patients in the PAP group

From: Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study

Factor Univariate analysis Multivariate analysis
Patients with proven/probable IFD (n/N) Incidence of proven/probable IFD (%) Comparison (P value) SE OR (95 % CI) Comparison (P value)
Age
 ≤18 years old 9/182 4.95 0.15 0.44 2.78 (1.18–6.55) 0.02
 >18 years old 54/636 8.49     
Transplantation type
 HLA-matched related (sibling) 10/335 2.99 0.0001    
 Haploidentical 31/269 11.52   0.65 6.08 (1.69–21.86) 0.01
 Unrelated 22/213 10.33   0.60 8.07 (2.50–26.10) 0.00
Antithymocyte globulin
 Yes 49/516 4.64 0.01 0.57 0.40 (0.13–1.24) 0.11
 No 14/302 9.50     
Glucocorticoidsa
 Yes 58/678 8.55 0.05 0.58 1.37 (0.44–4.23) 0.58
 No 5/140 3.57     
GVHDb
 Non-GVHD 31/428 7.24 0.15 0.40 1.63 (0.74–3.58) 0.22
 aGVHD I–II 16/230 6.96     
 aGVHD III–IV 8/52 15.38     
 cGVHD local 2/60 3.33     
 cGVHD extensive 3/27 11.11     
Prolonged, profound neutropenia
 ANC > 500/mm3 1/14 7.14 0.0006    
 ANC < 500/mm3, <10 days 6/142 4.23   1.22 0.40 (0.04–4.33) 0.45
 ANC < 500/mm3, 10–14 days 4/176 2.27   1.28 0.14 (0.01–1.73) 0.13
 ANC < 500/mm3, >14 days 52/486 10.70   1.16 0.99 (0.10–9.60) 0.99
EBV viremiac
 Yes 10/62 16.13 0.03 0.44 1.35 (0.58–3.17) 0.49
 No 43/646 6.66     
 Untested 10/110 9.09     
CMV viremiac
 Yes 33/267 12.36 0.004 0.33 1.18 (0.61–2.26) 0.63
 No 29/528 5.49     
 Untested 1/23 4.35     
Renal impairment
 Yes 10/60 16.67 0.019 0.43 1.38 (0.59–3.24) 0.46
 No 53/758 6.99     
Decreased albumin
 Yes 39/317 12.30 0.0001 0.31 1.98 (1.08–3.62) 0.03
 No 24/501 4.79     
Time of IFD prophylaxis
 <35 days 33/396 8.33 0.60 0.30 1.33 (0.74–2.39) 0.35
 ≥35 days 30/416 7.21     
Drugs for IFD prophylaxis
 Fluconazole/fluconazole + itraconazolee 39/498 7.83 0.17 0.46 1.76 (0.72–4.31) 0.21
 Itraconazolee 14/103 13.59   0.53 3.14 (1.11–8.86) 0.03
 Voriconazolee 2/71 2.82   0.85 0.95 (0.18–5.01) 0.95
 Otherd 8/144 5.56     
  1. ANC absolute neutrophil count, EBV Epstein-Barr virus
  2. aIncluding dexamethasone, methylprednisolone, prednisone, and hydrocortisone
  3. bBy multivariate analysis, OR is for cGVHD extensive/aGVHD III and IV degree versus cGVHD local/aGVHD I and II degree/non-GVHD
  4. cBy multivariate analysis, OR is for with EBV viremia versus without EBV viremia or untested/CMV viremia versus without CMV viremia or untested
  5. dIncluding caspofungin, micafungin, amphotericin B, fluconazole + caspofungin, fluconazole + micafungin, fluconazole + voriconazole, itraconazole + micafungin, voriconazole + caspofungin, and fluconazole + caspofungin + voriconazole
  6. eCompared with others
  7. The italicized data reflected significant difference